From Yahoo Finance: 2025-05-20 10:00:00

Carillon Tower Advisers released its “Carillon Eagle Growth & Income Fund” Q1 2025 investor letter, noting a 4.3% S&P 500 decline and market volatility triggered by policy uncertainties, economic slowdowns, and AI investment sustainability concerns. The quarter saw a market rotation favoring defensive sectors, quality stocks, and dividend-yielding equities over growth investments.

AbbVie Inc. (NYSE:ABBV) was highlighted in the investor letter as a strong stock pick, with a one-month return of 6.74% and a 13.84% gain over 52 weeks. The company closed at $185.71 per share on May 19, 2025, with a market capitalization of $327.809 billion. AbbVie’s 2025 guidance and sales outlook boosted its performance amid a market rotation into healthcare.

AbbVie Inc. (NYSE:ABBV) is not among the 30 most popular stocks among hedge funds, but 85 hedge fund portfolios held it at the end of Q4, up from 68 in Q3. While AbbVie shows investment potential, AI stocks are favored for higher returns in a shorter timeframe. Investors seeking promising AI stocks can explore an undervalued option with significant upside potential.

Read more: AbbVie (ABBV) Soared on Favorable Tailwinds